Metoclopramide in the treatment of diabetic gastroparesis

References

• Stanghellini V, Tosetti C, Paternico A et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology110(4), 1036–1042 (1996).
   PubMed Web of Science ®Google Scholar
• Soykan I, Sivri B, Sarosiek I, Kiernan B, McCallum RW. Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Dig. Dis. Sci.43(11), 2398–2404 (1998).
   PubMed Web of Science ®Google Scholar
• Kristensson K, Nordborg C, Olsson Y, Sourander P. Changes in the vagus nerve in diabetes mellitus. Acta Pathol. Microbiol. Scand.79(6), 684–685 (1971).
   Google Scholar
• Merio R, Festa A, Bergmann H et al. Slow gastric emptying in Type I diabetes: relation to autonomic and peripheral neuropathy, blood glucose, and glycemic control. Diabetes Care20(3), 419–423 (1997).
   PubMed Web of Science ®Google Scholar
• Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation115(3), 387–397 (2007).
   PubMed Web of Science ®Google Scholar
• Rothstein RD. Gastrointestinal motility disorders in diabetes mellitus. Am. J. Gastroenterol.85(7), 782–785 (1990).
   PubMedGoogle Scholar
• Sanger GJ, Lee K. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders. Nat. Rev. Drug Discov.7(3), 241–254 (2008).
   PubMed Web of Science ®Google Scholar
• Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum R. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J. Gastrointest. Surg.9(1), 102–108 (2005).
   PubMed Web of Science ®Google Scholar
• Parkman HP, Camilleri M, Farrugia G et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol. Motil.22(2), 113–133 (2010).
   Google Scholar
• Hasler WL. Gastroparesis: symptoms, evaluation, and treatment. Gastroenterol. Clin. North Am.36, 619–647 (2007).
   PubMed Web of Science ®Google Scholar
• Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia37(6), 543–551 (1994).
   PubMed Web of Science ®Google Scholar
• Kong MF, Horowitz M. Gastric emptying in diabetes mellitus: relationship to blood-glucose control. Clin. Geriatr. Med.15(2), 321–338 (1999).
   PubMed Web of Science ®Google Scholar
• Snape WJ Jr, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind, controlled trial. Ann. Intern. Med.96(4), 444–446 (1982).
   PubMed Web of Science ®Google Scholar
• Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment. Pharmacol. Ther.31(1), 11–19 (2010).
   PubMed Web of Science ®Google Scholar
• Justin-Besancon L, Laville C. [Antiemetic action of metoclopramide with respect to apomorphine and hydergine]. CR Seances Soc. Biol. Fil.158, 723–727 (1964).
   PubMedGoogle Scholar
• Shaffer D, Butterfield M, Pamer C, Mackey AC. Tardive dyskinesia risks and metoclopramide use before and after U.S. market withdrawal of cisapride. J. Am. Pharm. Assoc. (2003)44(6), 661–665 (2004).
   PubMedGoogle Scholar
• Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab. Dispos.30(3), 336–343 (2002).
   PubMed Web of Science ®Google Scholar
• Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin. Pharmacokinet.8(6), 523–529 (1983).
   PubMed Web of Science ®Google Scholar
• Magueur E, Hagege H, Attali P, Singlas E, Etienne JP, Taburet AM. Pharmacokinetics of metoclopramide in patients with liver cirrhosis. Br. J. Clin. Pharmacol.31(2), 185–187 (1991).
   PubMed Web of Science ®Google Scholar
• Bateman DN, Gokal R, Dodd TR, Blain PG. The pharmacokinetics of single doses of metoclopramide in renal failure. Eur. J. Clin. Pharmacol.19(6), 437–441 (1981).
   PubMed Web of Science ®Google Scholar
• Muller DJ, Shinkai T, De Luca V, Kennedy JL. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J.4(2), 77–87 (2004).
   PubMed Web of Science ®Google Scholar
• Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab. Dispos.27(9), 1078–1084 (1999).
   PubMed Web of Science ®Google Scholar
• Wolf CR, Smith G, Smith RL. Science, medicine, and the future: pharmacogenetics. Br. J. Med.320(7240), 987–990 (2000).
   PubMed Web of Science ®Google Scholar
• Vella A, Lee JS, Camilleri M et al. Effects of pramlintide, an amylin analogue, on gastric emptying in Type 1 and 2 diabetes mellitus. Neurogastroenterol. Motil.14(2), 123–131 (2002).
   PubMed Web of Science ®Google Scholar
• Ratner RE, Dickey, R, Fineman M et al. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet. Med.21(11), 1204–1212 (2004).
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes: a randomized trial. Ann. Intern. Med.143(8), 559–569 (2005).
   PubMed Web of Science ®Google Scholar
• Talley SJ, Bytzer P, Hammer J, Young L, Jones M, Horowitz M. Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus. Am. J. Gastroenterol.96(4), 1033–1038 (2001).
   Google Scholar
• Yu J, Paine MJ, Marechal JD et al.In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide. Drug Metab. Dispos.34(8), 1386–1392 (2006).
   PubMed Web of Science ®Google Scholar
• Valenzuela JE, Dooley C. Dopamine antagonists in the upper gastrointestinal tract. Scand. J. Gastroenterol. Suppl.96, 127–136 (1984).
   PubMedGoogle Scholar
• Tonini M, Cipollina L, Poluzzi E, Crema F, Corazza GR, De Ponti F. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment. Pharmacol. Ther.19(4), 379–390 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez AG, Massingham R. Peripheral receptor populations involved in the regulation of gastrointestinal motility and the pharmacological actions of metoclopramide-like drugs. Life Sci.36(1), 1–14 (1985).
   PubMed Web of Science ®Google Scholar
• Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann. Intern. Med.98(1), 86–95 (1983).
   PubMed Web of Science ®Google Scholar
• Clarke DE, Craig DA, Fozard JR. The 5-HT4 receptor: naughty, but nice. Trends Pharmacol. Sci.10(10), 385–386 (1989).
   PubMed Web of Science ®Google Scholar
• Dumitrascu DL, Ungureanu O, Verzea D, Pascu O. The effect of metoclopramide on antral emptying of a semisolid meal in patients with functional dyspepsia. A randomized placebo controlled sonographic study. Rom. J. Intern. Med.36(1–2), 97–104 (1998).
   Google Scholar
• Kishibayashi N, Karasawa A. Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats. Jpn J. Pharmacol.67(1), 45–50 (1995).
   Google Scholar
• Lang IM, Sarna SK, Condon RE. Gastrointestinal motor correlates of vomiting in the dog: quantification and characterization as an independent phenomenon. Gastroenterology90(1), 40–47 (1986).
   PubMed Web of Science ®Google Scholar
• Mitchelson F. Pharmacological agents affecting emesis. A review (part I). Drugs43(3), 295–315 (1992).
   PubMed Web of Science ®Google Scholar
• Mahajan HS, Gattani S. In situ gels of metoclopramide hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. Drug Deliv.17(1), 19–27 (2010).
   PubMed Web of Science ®Google Scholar
• McCallum RW, Valenzuela G, Polepalle S, Spyker D. Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics. J. Pharmacol. Exp. Ther.258(1), 136–142 (1991).
   PubMed Web of Science ®Google Scholar
• Brownlee M, Kroopf SS. Letter: metoclopramide for gastroparesis diabeticorum. N. Engl. J. Med.291(23), 1257–1258 (1974).
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Malagelada JR, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann. Intern. Med.86(2), 195–196 (1977).
   PubMed Web of Science ®Google Scholar
• Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double-blind study. Dig. Dis. Sci.24(9), 662–666 (1979).
   PubMed Web of Science ®Google Scholar
• McCallum RW, Ricci DA, Rakatansky H et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care6(5), 463–467 (1983).
   PubMed Web of Science ®Google Scholar
• Loo FD, Palmer DW, Soergel KH, Kalbfleisch JH, Wood CM. Gastric emptying in patients with diabetes mellitus. Gastroenterology86(3), 485–494 (1984).
   PubMed Web of Science ®Google Scholar
• Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J. Clin. Gastroenterol.7(1), 25–32 (1985).
   PubMed Web of Science ®Google Scholar
• Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care16(11), 1511–1514 (1993).
   PubMed Web of Science ®Google Scholar
• Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am. J. Gastroenterol.94(5), 1230–1234 (1999).
   PubMed Web of Science ®Google Scholar
• Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann. Pharmacother.37(1), 122–126 (2003).
   PubMedGoogle Scholar
• Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, Van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig. Dis. Sci.30(1), 10–15 (1985).
   PubMed Web of Science ®Google Scholar
• Chen JD, Pan J, McCallum RW. Clinical significance of gastric myoelectrical dysrhythmias. Dig. Dis.13(5), 275–290 (1995).
   PubMedGoogle Scholar
• Bradette M, Pare P, Douville P, Morin A. Visceral perception in health and functional dyspepsia. Crossover study of gastric distension with placebo and domperidone. Dig. Dis. Sci.36(1), 52–58 (1991).
   PubMed Web of Science ®Google Scholar
• Banner SE, Sanger GJ. Differences between 5-HT3 receptor antagonists in modulation of visceral hypersensitivity. Br. J. Pharmacol.114(2), 558–562 (1995).
   PubMed Web of Science ®Google Scholar
• Rowbotham DJ, Bamber PA, Nimmo WS. Comparison of the effect of cisapride and metoclopramide on morphine-induced delay in gastric emptying. Br. J. Clin. Pharmacol.26(6), 741–746 (1988).
   Google Scholar
• de Caestecker JS, Ewing DJ, Tothill P, Clarke BF, Heading RC. Evaluation of oral cisapride and metoclopramide in diabetic autonomic neuropathy: an eight-week double-blind crossover study. Aliment. Pharmacol. Ther.3(1), 69–81 (1989).
   PubMedGoogle Scholar
• Suchitra AD, Dkhar SA, Shewade DG, Shashindran CH. Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice. World J. Gastroenterol.9(4), 779–783 (2003).
   PubMedGoogle Scholar
• Kelly J, Alheid GF, McDermott L, Halaris A, Grossman SP. Behavioral and biochemical effects of knife cuts that preferentially interrupt principal afferent and efferent connections of the striatum in the rat. Pharmacol. Biochem. Behav.6(1), 31–45 (1977).
   Google Scholar
• Quenzer LF, Galli CL, Neff NH. Activation of the nigrostriatal dopaminergic pathway by injection of cholera enterotoxin into the substantia nigra. Science195(4273), 78–80 (1977).
   Google Scholar
• Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr. Rev.22(6), 724–763 (2001).
   PubMed Web of Science ®Google Scholar
• Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology127(5), 1592–1622 (2004).
   PubMed Web of Science ®Google Scholar
• Jolliet P, Nion S, Allain-Veyrac G. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared with domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood–brain barrier. Pharmacol. Res.56(1), 11–17 (2007).
   PubMed Web of Science ®Google Scholar
• Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch. Intern. Med.149(11), 2486–2492 (1989).
   PubMed Web of Science ®Google Scholar
• Pasricha PJ, Pehlivanov N, Sugumar A, Jankovic J. Drug insight: from disturbed motility to disordered movement – a review of the clinical benefits and medicolegal risks of metoclopramide. Nat. Clin. Pract. Gastroenterol. Hepatol.3(3), 138–148 (2006).
   PubMedGoogle Scholar
• van der Padt A, van Schaik RH, Sonneveld P. Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms. Neth. J. Med.64(5), 160–162 (2006).
   PubMed Web of Science ®Google Scholar
• Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br. Med. J. (Clin. Res. Ed.)291(6500), 930–932 (1985).
   PubMed Web of Science ®Google Scholar
• Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch. Intern. Med.153(12), 1469–1475 (1993).
   PubMed Web of Science ®Google Scholar
• McCallum RW, Ippoliti AF, Cooney C, Sturdevant RA. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N. Engl. J. Med.296(7), 354–357 (1977).
   PubMed Web of Science ®Google Scholar
• Jungmann E, Schoffling K. Akathisia and metoclopramide. Lancet2(8291), 221 (1982).
   PubMed Web of Science ®Google Scholar
• Regan LA, Hoffman RS, Nelson LS. Slower infusion of metoclopramide decreases the rate of akathisia. Am. J. Emerg. Med.27(4), 475–480 (2009).
   Web of Science ®Google Scholar
• Avorn J, Gurwitz JH, Bohn RL, Mogun H, Monane M, Walker A. Increased incidence of levodopa therapy following metoclopramide use. JAMA274(22), 1780–1782 (1995).
   PubMed Web of Science ®Google Scholar
• Abell TL, Bernstein RK, Cutts T et al. Treatment of gastroparesis: a multidisciplinary clinical review. Neurogastroenterol. Motil.18(4), 263–283 (2006).
   PubMed Web of Science ®Google Scholar
• Wiholm BE, Mortimer O, Boethius G, Haggstrom JE. Tardive dyskinesia associated with metoclopramide. Br. Med. J. (Clin. Res. Ed.)288(6416), 545–547 (1984).
   PubMedGoogle Scholar
• Kenney C, Hunter C, Davidson A, Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J. Clin. Pharmacol.48(3), 379–384 (2008).
   PubMed Web of Science ®Google Scholar
• Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV. Metoclopramide and tardive dyskinesia. Biol. Psychiatry36(9), 630–632 (1994).
   PubMed Web of Science ®Google Scholar
• Sewell DD, Jeste DV. Metoclopramide-associated tardive dyskinesia. An analysis of 67 cases. Arch. Fam. Med.1(2), 271–278 (1992).
   PubMedGoogle Scholar
• Cooper BT, Mountford RA, McKee C. Galactorrhoea, hyperprolactinaemia, and pituitary adenoma presenting during metoclopramide therapy. Postgrad. Med. J.58(679), 314–315 (1982).
   PubMedGoogle Scholar
• Maddern GJ. Galactorrhoea due to domperidone. Med. J. Aust.2(11), 539–540 (1983).
   Google Scholar
• Kaufman JM, Elewaut A, Vermeulen A. Effect of domperidone on prolactin (PRL)and thyrotrophin (TSH) secretion. Arch. Int. Pharmacodyn. Ther.254(2), 293–303 (1981).
   Google Scholar
• Corazza GR, Biagi F, Albano O et al. Levosulpiride in functional dyspepsia: a multicentric, double-blind, controlled trial. Ital. J. Gastroenterol.28(6), 317–323 (1996).
   PubMedGoogle Scholar
• Hyett B, Martinez FJ, Gill BM et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology137(2), 445–452 (2009).
   PubMedGoogle Scholar
• Jung HK, Choung RS, Locke GR 3rd et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology136(4), 1225–1233 (2009).
   PubMed Web of Science ®Google Scholar